Clinical Trials Browser

LOCALLY ADVANCED CERVICAL CANCERS

NCT03245892 2025-12-17

A Study of Carboplatin and Paclitaxel Chemotherapy With Nivolumab With or Without Ipilimumab in Patients With Ovarian Cancer

Phase 1 Completed

27 enrolled

Gynecologic

High Grade Serous Ovarian

NCT04157985 2025-12-11

Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid Tumors

Phase 3 Completed

161 enrolled

DermatologicGastrointestinalGenitourinaryGynecologicHead & Neck

Squamous Cell Carcinoma of Head and Neck, Anus Neoplasms, Urinary Bladder Neoplasms, Uterine Cervical Neoplasms, Carcinoma, Hepatocellular, Kidney Neoplasms, Melanoma, Stomach Neoplasms, Colorectal Neoplasms, Carcinoma, Merkel Cell, Cholangiocarcinoma

NCT07223424 2025-11-10

PSI-Immune

Phase 2 Recruiting

480 enrolled

DermatologicGastrointestinalGenitourinaryGynecologicThoracic

Adenocarcinoma Of Esophagus, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Squamous Cell, Uterine Cervical Neoplasms, Colitis, Ulcerative, Colonic Neoplasms, Esophageal Neoplasms, Carcinoma, Hepatocellular, Melanoma

NCT03355976 2025-10-09

BrUOG 354 Nivolumab +/- Ipilimumab for Ovarian and Extra-renal Clear Cell Carcinomas

Phase 2 Active not recruiting

46 enrolled

Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms, Recurrence, Adenocarcinoma, Clear Cell

NCT04954599 2025-10-07

Phase 1/2 Clinical Trial of CP-506 (HAP) in Monotherapy or With Carboplatin or ICI

Phase 1/2 Recruiting

126 enrolled

BreastGastrointestinalGenitourinaryGynecologicHead & Neck

Head and Neck Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Triple Negative Breast Neoplasms

NCT04611126 2025-08-12

T-cell Therapy in Combination With Nivolumab, Relatlimab and Ipilimumab for Patients With Metastatic Ovarian Cancer

Phase 1/2 Terminated

6 enrolled 11 charts

Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT04024878 2025-06-18

NeoVax With Nivolumab in Patients With Ovarian Cancer

Phase 1 Active not recruiting

22 enrolled

Gynecologic

Ovarian Neoplasms

NCT02873962 2025-06-08

A Phase II Study Of Nivolumab/ Bevacizumab/Rucaparib

Phase 2 Active not recruiting

73 enrolled

Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT06638931 2025-05-28

ANTARES

Phase 2 Active not recruiting

28 enrolled

BreastCNSEndocrineGastrointestinalGenitourinaryGynecologicHead & NeckNETOther solid neoplasmSarcomaThoracic

Urachal adenocarcinoma, Urachal cancer, Fibrolamellar hepatocellular carcinoma, Secretory breast carcinoma, Carcinoma, Ovarian Epithelial, Adrenal Gland Neoplasms, Anus Neoplasms, Biliary Tract Neoplasms, Carcinosarcoma, Carcinoma, Adenoid Cystic, Fallopian Tube Neoplasms, Fibrosarcoma, Gallbladder Neoplasms, Granulosa Cell Tumor, Hemangiosarcoma, Leiomyosarcoma, Mesothelioma, Neuroblastoma, Parathyroid Neoplasms, Penile Neoplasms, Sarcoma, Sarcoma, Kaposi, Osteosarcoma, Thyroid Neoplasms, Trophoblastic Neoplasms, Urethral Neoplasms, Vaginal Neoplasms, Vulvar Neoplasms, Hepatoblastoma, Endodermal Sinus Tumor, Neuroectodermal Tumors, Primitive, Cholangiocarcinoma, Sertoli-Leydig Cell Tumor, Neurofibrosarcoma, Hemangioblastoma, Neuroendocrine Tumors

NCT03508570 2025-05-22

Nivolumab With or Without Ipilimumab in Treating Patients With Recurrent or High Grade Gynecologic Cancer With Metastatic Peritoneal Carcinomatosis

Phase 1 Completed

26 enrolled

Gynecologic

Uterine Cervical Neoplasms, Fallopian Tube Neoplasms, Ovarian Neoplasms, Peritoneal Neoplasms, Endometrial Neoplasms

NCT05715216 2025-05-16

EON: A Single-arm Phase II Study of Etigilimab (OMP-313M32) in Combination With Checkpoint Inhibition (Nivolumab) in Patients With Platinum-resistant, Recurrent Epithelial Ovarian Cancer

Phase 2 Active not recruiting

20 enrolled

Gynecologic

Ovarian Neoplasms

NCT05795244 2025-05-13

Study of Induction PD-1 Blockade (Nivolumab) in Patients With Surgically Complete Resectable Mismatch Repair Deficient Endometrial Cancer (NIVEC)

Phase 2 Recruiting

30 enrolled

Gynecologic

Endometrial Neoplasms

NCT03241745 2024-12-27

A Study of Nivolumab in Selected Uterine Cancer Patients

Phase 2 Completed

35 enrolled 8 charts

GynecologicSarcoma

Carcinosarcoma, Leiomyosarcoma, Uterine Neoplasms, Endometrial Neoplasms, Adenocarcinoma, Clear Cell

NCT04256213 2024-12-12

COLIBRI

Phase NA Completed

40 enrolled

Gynecologic

Uterine Cervical Neoplasms

NCT03172416 2024-05-29

PIPAC

Phase 1 Active not recruiting

21 enrolled

GastrointestinalGynecologic

Peritoneal Neoplasms, Stomach Neoplasms

NCT05492123 2024-01-05

Nivolumab-ipilimumab and Chemoradiation for Cervical Cancer

Phase 2 Recruiting

112 enrolled

Gynecologic

Uterine Cervical Neoplasms

NCT05504642 2023-04-18

CERAD-IMMUNE

Phase 2 Withdrawn

Gynecologic

Uterine Cervical Neoplasms, Lymphatic Metastasis

NCT02737787 2023-04-07

A Phase I Study of WT1 or NY-ESO-1 Vaccine and Nivolumab For Recurrent Ovarian Cancer

Phase 1 Completed

11 enrolled

Gynecologic

Neoplasm Metastasis, Ovarian Neoplasms

NCT03287674 2023-03-01

TIL Therapy in Combination With Checkpoint Inhibitors for Metastatic Ovarian Cancer

Phase 1/2 Completed

7 enrolled 10 charts

Gynecologic

Ovarian Neoplasms

NCT04434560 2022-07-26

Neoadjuvant Immunotherapy in Brain Metastases

Phase 2 Terminated

1 enrolled 7 charts

BreastCNSDermatologicGenitourinaryGynecologicThoracic

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Melanoma, Ovarian Neoplasms, Triple Negative Breast Neoplasms

NCT03100006 2022-06-13

ORION-01

Phase 1/2 Terminated

13 enrolled

Gynecologic

Carcinoma, Ovarian Epithelial

NCT04620954 2021-12-01

ORION-02

Phase 1/2 Unknown

31 enrolled

Gynecologic

Carcinoma, Ovarian Epithelial

NCT03572478 2021-03-09

Rucaparib and Nivolumab in Patients With Prostate or Endometrial Cancer

Phase 1/2 Terminated

12 enrolled 7 charts

GenitourinaryGynecologic

Prostatic Neoplasms, Endometrial Neoplasms

Clinical Trials

COLIBRI-2

A Study of Carboplatin and Paclitaxel Chemotherapy With Nivolumab With or Without Ipilimumab in Patients With Ovarian Cancer

Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid Tumors

PSI-Immune

BrUOG 354 Nivolumab +/- Ipilimumab for Ovarian and Extra-renal Clear Cell Carcinomas

Phase 1/2 Clinical Trial of CP-506 (HAP) in Monotherapy or With Carboplatin or ICI

T-cell Therapy in Combination With Nivolumab, Relatlimab and Ipilimumab for Patients With Metastatic Ovarian Cancer

NeoVax With Nivolumab in Patients With Ovarian Cancer

A Phase II Study Of Nivolumab/ Bevacizumab/Rucaparib

ANTARES

Nivolumab With or Without Ipilimumab in Treating Patients With Recurrent or High Grade Gynecologic Cancer With Metastatic Peritoneal Carcinomatosis

EON: A Single-arm Phase II Study of Etigilimab (OMP-313M32) in Combination With Checkpoint Inhibition (Nivolumab) in Patients With Platinum-resistant, Recurrent Epithelial Ovarian Cancer

Study of Induction PD-1 Blockade (Nivolumab) in Patients With Surgically Complete Resectable Mismatch Repair Deficient Endometrial Cancer (NIVEC)

A Study of Nivolumab in Selected Uterine Cancer Patients

COLIBRI

PIPAC

Nivolumab-ipilimumab and Chemoradiation for Cervical Cancer

CERAD-IMMUNE

A Phase I Study of WT1 or NY-ESO-1 Vaccine and Nivolumab For Recurrent Ovarian Cancer

TIL Therapy in Combination With Checkpoint Inhibitors for Metastatic Ovarian Cancer

Neoadjuvant Immunotherapy in Brain Metastases

ORION-01

ORION-02

Rucaparib and Nivolumab in Patients With Prostate or Endometrial Cancer